Loading...

We've got a brand new version of Simply Wall St! Try it out

InDex Pharmaceuticals Holding

OM:INDEX
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INDEX
OM
SEK574M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

InDex Pharmaceuticals Holding AB (publ) develops pharmaceuticals for patients with ulcerative colitis. The last earnings update was 3 days ago. More info.


Add to Portfolio Compare Print
INDEX Share Price and Events
7 Day Returns
-1%
OM:INDEX
-5.2%
SE Pharmaceuticals
-1.2%
SE Market
1 Year Returns
18.8%
OM:INDEX
-8.3%
SE Pharmaceuticals
-2.6%
SE Market
INDEX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
InDex Pharmaceuticals Holding (INDEX) -1% -4.4% 5.6% 18.8% - -
SE Pharmaceuticals -5.2% -4% -5.8% -8.3% 9.3% -19.8%
SE Market -1.2% -3.6% -2.8% -2.6% 6.6% 14.3%
1 Year Return vs Industry and Market
  • INDEX outperformed the Pharmaceuticals industry which returned -8.3% over the past year.
  • INDEX outperformed the Market in Sweden which returned -2.6% over the past year.
Price Volatility
INDEX
Industry
5yr Volatility vs Market

Value

 Is InDex Pharmaceuticals Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for InDex Pharmaceuticals Holding. This is due to cash flow or dividend data being unavailable. The share price is SEK8.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for InDex Pharmaceuticals Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are InDex Pharmaceuticals Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:INDEX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in SEK SEK-1.08
OM:INDEX Share Price ** OM (2019-08-16) in SEK SEK8.34
Europe Pharmaceuticals Industry PE Ratio Median Figure of 46 Publicly-Listed Pharmaceuticals Companies 26.53x
Sweden Market PE Ratio Median Figure of 322 Publicly-Listed Companies 15.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of InDex Pharmaceuticals Holding.

OM:INDEX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:INDEX Share Price ÷ EPS (both in SEK)

= 8.34 ÷ -1.08

-7.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InDex Pharmaceuticals Holding is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • InDex Pharmaceuticals Holding is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does InDex Pharmaceuticals Holding's expected growth come at a high price?
Raw Data
OM:INDEX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 37 Publicly-Listed Pharmaceuticals Companies 1.89x
Sweden Market PEG Ratio Median Figure of 236 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for InDex Pharmaceuticals Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on InDex Pharmaceuticals Holding's assets?
Raw Data
OM:INDEX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in SEK SEK0.36
OM:INDEX Share Price * OM (2019-08-16) in SEK SEK8.34
Sweden Pharmaceuticals Industry PB Ratio Median Figure of 19 Publicly-Listed Pharmaceuticals Companies 4.23x
Sweden Market PB Ratio Median Figure of 576 Publicly-Listed Companies 2.55x
OM:INDEX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:INDEX Share Price ÷ Book Value per Share (both in SEK)

= 8.34 ÷ 0.36

22.95x

* Primary Listing of InDex Pharmaceuticals Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InDex Pharmaceuticals Holding is overvalued based on assets compared to the SE Pharmaceuticals industry average.
X
Value checks
We assess InDex Pharmaceuticals Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. InDex Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is InDex Pharmaceuticals Holding expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InDex Pharmaceuticals Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is InDex Pharmaceuticals Holding expected to grow at an attractive rate?
  • Unable to compare InDex Pharmaceuticals Holding's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare InDex Pharmaceuticals Holding's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare InDex Pharmaceuticals Holding's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:INDEX Future Growth Rates Data Sources
Data Point Source Value (per year)
Sweden Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11%
Sweden Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.1%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:INDEX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:INDEX Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OM:INDEX Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -69 -72
2019-03-31 0 -75 -81
2018-12-31 0 -79 -82
2018-09-30 0 -73 -82
2018-06-30 0 -73 -80
2018-03-31 0 -72 -69
2017-12-31 0 -68 -73
2017-09-30 0 -83 -67
2017-06-30 0 -74 -61
2017-03-31 0 -64 -56
2016-12-31 0 -32 -41
2016-09-30 0 -11 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if InDex Pharmaceuticals Holding is high growth as no earnings estimate data is available.
  • Unable to determine if InDex Pharmaceuticals Holding is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:INDEX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from InDex Pharmaceuticals Holding Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:INDEX Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OM:INDEX Past Financials Data
Date (Data in SEK Millions) EPS *
2019-06-30 -1.08
2019-03-31 -1.24
2018-12-31 -1.29
2018-09-30 -1.32
2018-06-30 -1.28
2018-03-31 -1.11
2017-12-31 -1.16
2017-09-30 -1.07
2017-06-30 -1.12
2017-03-31 -1.22
2016-12-31 -1.08
2016-09-30 -1.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if InDex Pharmaceuticals Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine InDex Pharmaceuticals Holding's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. InDex Pharmaceuticals Holding's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. InDex Pharmaceuticals Holding's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess InDex Pharmaceuticals Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
InDex Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has InDex Pharmaceuticals Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare InDex Pharmaceuticals Holding's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • InDex Pharmaceuticals Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare InDex Pharmaceuticals Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare InDex Pharmaceuticals Holding's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
InDex Pharmaceuticals Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from InDex Pharmaceuticals Holding Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:INDEX Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.10 -72.48 78.99
2019-03-31 0.11 -80.79 87.10
2018-12-31 0.13 -82.32 88.53
2018-09-30 0.13 -82.26 81.96
2018-06-30 0.12 -80.27 79.88
2018-03-31 0.13 -69.47 69.18
2017-12-31 0.11 -72.76 64.42
2017-09-30 0.13 -66.70 53.70
2017-06-30 0.15 -60.96 48.06
2017-03-31 0.16 -56.24 40.81
2016-12-31 0.18 -41.28 33.57
2016-09-30 0.20 -31.47 28.42
2016-06-30 0.21 -31.32 28.54
2016-03-31 0.29 -28.90 27.85
2015-12-31 0.38 -29.88 28.33
2015-09-30 0.37 -33.06 30.37
2015-06-30 0.39 -35.51 31.52
2015-03-31 22.78 -25.19 41.88
2014-12-31 45.16 -14.87 52.24
2013-12-31 0.50 -68.42 61.89
2012-12-31 0.64 -51.36 50.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if InDex Pharmaceuticals Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if InDex Pharmaceuticals Holding has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if InDex Pharmaceuticals Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess InDex Pharmaceuticals Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
InDex Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is InDex Pharmaceuticals Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up InDex Pharmaceuticals Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • InDex Pharmaceuticals Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • InDex Pharmaceuticals Holding has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of InDex Pharmaceuticals Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • InDex Pharmaceuticals Holding has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from InDex Pharmaceuticals Holding Company Filings, last reported 1 month ago.

OM:INDEX Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 25.00 0.00 50.53
2019-03-31 42.69 0.00 64.40
2018-12-31 59.91 0.00 83.03
2018-09-30 44.88 0.00 66.42
2018-06-30 60.00 0.00 82.48
2018-03-31 86.00 0.00 102.15
2017-12-31 104.75 0.00 125.06
2017-09-30 127.14 0.00 139.13
2017-06-30 140.24 0.00 155.71
2017-03-31 155.43 0.00 174.13
2016-12-31 177.47 0.00 193.23
2016-09-30 -24.40 0.00 3.67
2016-06-30 -17.00 0.00 11.18
2016-03-31 0.55 0.00 6.96
2015-12-31 0.55 0.00 6.96
2015-09-30
2015-06-30 14.29 0.00 22.21
2015-03-31 30.40 0.00 43.89
2014-12-31 30.40 0.00 43.89
2013-12-31 15.11 0.00 21.95
2012-12-31 -13.83 0.00 40.17
  • InDex Pharmaceuticals Holding has no debt.
  • InDex Pharmaceuticals Holding has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • InDex Pharmaceuticals Holding has less than a year of cash runway based on current free cash flow.
  • InDex Pharmaceuticals Holding has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.
X
Financial health checks
We assess InDex Pharmaceuticals Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. InDex Pharmaceuticals Holding has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is InDex Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from InDex Pharmaceuticals Holding dividends.
If you bought SEK2,000 of InDex Pharmaceuticals Holding shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate InDex Pharmaceuticals Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate InDex Pharmaceuticals Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:INDEX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 30 Stocks 3%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 244 Stocks 3.7%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.3%
Sweden Bottom 25% Dividend Yield 25th Percentile 2%
Sweden Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:INDEX Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as InDex Pharmaceuticals Holding has not reported any payouts.
  • Unable to verify if InDex Pharmaceuticals Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of InDex Pharmaceuticals Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as InDex Pharmaceuticals Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess InDex Pharmaceuticals Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can InDex Pharmaceuticals Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. InDex Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of InDex Pharmaceuticals Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Zerhouni
AGE 47
TENURE AS CEO 3.6 years
CEO Bio

Mr. Peter Zerhouni, M.Sc., BSc has been Chief Executive Officer at InDex Pharmaceuticals Holding AB (publ) since 2016. Mr. Zerhouni has been Chief Executive Officer of InDex Pharmaceuticals AB and InDex Diagnostics AB since April 2015. He serves as auditor of Reimersholmes Kooperativa Daghem ekonomiska förening. He served as the Chief Executive Officer and President of Diamyd Medical AB (publ) from 2011 to February 28, 2015 and served as its Head of Business Development. He has extensive experience in developing life science companies from both a scientific and commercial perspective. He served as Chief Executive Officer of Diamyd Medical Group until 2015 and Mertiva Diagnostics AB until 2013. He served as the President of Diamyd Therapeutics AB since April 22, 2013. He served as the Chief Executive Officer and President for Mertiva AB from July 4, 2011 to April 22, 2013 and also served as its Acting Chief Executive Officer and Acting President until July 4, 2011. Mr. Zerhouni served as an Executive Vice President of Mertiva AB since April 21, 2011 and served as its Senior Director of Business Development. He served as the Chief Financial Officer of Mertiva AB since May 1, 2008. He joined Mertiva AB in 2006. From 1999 to 2006, he held various positions at ING Bank in Brussels and Amsterdam, within Structured Finance. He served as Director of Cellaviva AB until 2015. Mr. Zerhouni received a M.Sc. in Biology and a B.Sc. in Economics and Business Administration from Lund University (part of the course work was completed at University of California at Berkely).

CEO Compensation
  • Insufficient data for Peter to compare compensation growth.
  • Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the InDex Pharmaceuticals Holding management team in years:

3.6
Average Tenure
56
Average Age
  • The tenure for the InDex Pharmaceuticals Holding management team is about average.
Management Team

Peter Zerhouni

TITLE
Chief Executive Officer
AGE
47
TENURE
3.6 yrs

Johan Giléus

TITLE
Chief Financial Officer
AGE
54
TENURE
2.3 yrs

Pernilla Sandwall

TITLE
Chief Operating Officer
AGE
56
TENURE
7.5 yrs

Thomas Knittel

TITLE
Chief Medical Officer
AGE
57
TENURE
7.6 yrs

Per-Olof Gunnesson

TITLE
Consultant
AGE
74
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the InDex Pharmaceuticals Holding board of directors in years:

3.6
Average Tenure
67
Average Age
  • The tenure for the InDex Pharmaceuticals Holding board of directors is about average.
Board of Directors

Wenche Rolfsen

TITLE
Chairman
COMPENSATION
SEK400K
AGE
67
TENURE
3.6 yrs

Uli Hacksell

TITLE
Director
COMPENSATION
SEK200K
AGE
69
TENURE
3.6 yrs

Lennart Hansson

TITLE
Director
COMPENSATION
SEK200K
AGE
63
TENURE
3.6 yrs

Stig Pedersen

TITLE
Director
COMPENSATION
SEK200K
AGE
58
TENURE
3.6 yrs

Gunther Hartmann

TITLE
Member of Scientific Advisory Board

Christopher Hawkey

TITLE
Member of Scientific Advisory Board

Robert Löfberg

TITLE
Member of Scientific Advisory Board

Markus Neurath

TITLE
Member of Scientific Advisory Board

Hans Wigzell

TITLE
Member of Scientific Advisory Board
AGE
81
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
20. May 19 Buy Johan Giléus Individual 17. May 19 17. May 19 10,000 SEK7.86 SEK78,600
01. Mar 19 Buy Stig Pedersen Individual 01. Mar 19 01. Mar 19 23,809 SEK7.78 SEK185,234
X
Management checks
We assess InDex Pharmaceuticals Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. InDex Pharmaceuticals Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

If You Had Bought InDex Pharmaceuticals Holding (STO:INDEX) Shares A Year Ago You'd Have Made 14%

To wit, the InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) share price is 14% higher than it was a year ago, much better than the market return of around 4.4% (not including dividends) in the same period. … Check out our latest analysis for InDex Pharmaceuticals Holding With just kr109,000 worth of revenue in twelve months, we don't think the market considers InDex Pharmaceuticals Holding to have proven its business plan. … Investors will be hoping that InDex Pharmaceuticals Holding can make progress and gain better traction for the business, before it runs low on cash.

Simply Wall St -

What Kind Of Shareholders Own InDex Pharmaceuticals Holding AB (publ) (STO:INDEX)?

The big shareholder groups in InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) have power over the company. … Insider Ownership Of InDex Pharmaceuticals Holding The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Private Company Ownership It seems that Private Companies own 4.2%, of the INDEX stock.

Simply Wall St -

Are Insiders Buying InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Stock?

So we'll take a look at whether insiders have been buying or selling shares in InDex Pharmaceuticals Holding AB (publ) (STO:INDEX). … The Last 12 Months Of Insider Transactions At InDex Pharmaceuticals Holding. … InDex Pharmaceuticals Holding may have bought shares in the last year, but they didn't sell any

Simply Wall St -

The InDex Pharmaceuticals Holding Share Price Has Gained 42% And Shareholders Are Hoping For More

For example, the InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) share price is up 42% in the last year, clearly besting than the market return of around -0.08% (not including dividends). … With just kr128,000 worth of revenue in twelve months, we don't think the market InDex Pharmaceuticals Holding has proven its business plan. … It seems likely some shareholders believe that InDex Pharmaceuticals Holding will significantly advance the business plan before too long.

Simply Wall St -

Is InDex Pharmaceuticals Holding AB (publ)'s (STO:INDEX) Balance Sheet A Threat To Its Future?

Zero-debt allows substantial financial flexibility, especially for small-cap companies like InDex Pharmaceuticals Holding AB (publ) (STO:INDEX), as the company does not have to adhere to strict debt covenants. … However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is INDEX growing fast enough to value financial flexibility over lower cost of capital

Simply Wall St -

Do Insiders Own Lots Of Shares In InDex Pharmaceuticals Holding AB (publ) (STO:INDEX)?

The big shareholder groups in InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) have power over the company. … InDex Pharmaceuticals Holding is a smaller company with a market capitalization of kr459m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

Should You Be Holding InDex Pharmaceuticals Holding AB (publ) (STO:INDEX)?

InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of INDEX, it

Simply Wall St -

Analysts Expect Breakeven For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX)

InDex Pharmaceuticals Holding AB (publ)'s (STO:INDEX):. … InDex Pharmaceuticals Holding AB (publ) develops pharmaceuticals for patients with ulcerative colitis. … The company’s loss has recently broadened since it announced a -kr73m loss in the full financial year, compared to the latest trailing-twelve-month loss of -kr80m, moving it further away from breakeven?

Simply Wall St -

Is InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) A Financially Sound Company?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is INDEX right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Should You Be Concerned About InDex Pharmaceuticals Holding AB (publ)'s (STO:INDEX) Shareholders?

In this article, I will take a quick look at InDex Pharmaceuticals Holding AB (publ)’s (STO:INDEX) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … Check out our latest analysis for InDex Pharmaceuticals Holding

Simply Wall St -

Company Info

Description

InDex Pharmaceuticals Holding AB (publ) develops pharmaceuticals for patients with ulcerative colitis. The company’s lead drug is Cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in discovery stage for use in the treatment of various immunological diseases. In addition, the company offers DiBiCol diagnostic kits to differentiate between ulcerative colitis and Crohn’s disease. InDex Pharmaceuticals Holding AB (publ) is headquartered in Stockholm, Sweden.

Details
Name: InDex Pharmaceuticals Holding AB (publ)
INDEX
Exchange: OM
Founded:
SEK573,635,833
68,781,275
Website: http://www.indexpharma.com
Address: InDex Pharmaceuticals Holding AB (publ)
Tomtebodavägen 23a,
Stockholm,
Stockholm County, 171 77,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM INDEX Class B Shares OMX Nordic Exchange Stockholm SE SEK 11. Oct 2016
Number of employees
Current staff
Staff numbers
7
InDex Pharmaceuticals Holding employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/18 21:59
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/02/20
Last earnings filing: 2019/08/15
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.